

Sorrento Therapeutics, Inc.
Form S-8
August 22, 2014

As filed with the Securities and Exchange Commission on August 22, 2014

Registration No.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

Sorrento Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

6042 Cornerstone Ct. West, Suite B

33-0344842
(I.R.S. Employer

Identification No.)

Edgar Filing: Sorrento Therapeutics, Inc. - Form S-8

San Diego, California 92121

(Address of principal executive offices) (Zip Code)

Amended and Restated 2009 Stock Incentive Plan

(Full title of the plans)

Dr. Henry Ji

Chief Executive Officer

Sorrento Therapeutics, Inc.

6042 Cornerstone Ct. West, Suite B

San Diego, CA 92121

(Name and Address of agent for service)

(858) 210-3700

(Telephone number, including area code, of agent for service)

With a copy to:

Jeffrey Fessler, Esq.

Sichenzia Ross Friedman FERENCE LLP

61 Broadway, 32nd Floor

New York, NY 10006

Phone (212) 930-9700

Fax (212) 930-9725

Edgar Filing: Sorrento Therapeutics, Inc. - Form S-8

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer
 Non-accelerated filer Smaller Reporting Company

CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered	Proposed		Proposed Maximum Aggregate Offering Price	Amount of Registration Fee
	Amount to be Registered (1)	Maximum Offering Price Per Share (2)		
Common Stock, \$.0001 par value	2,200,000	\$ 5.46	\$12,012,000	\$1,548

- (1) The securities to be registered hereby represent additional shares of common stock issuable under the Sorrento Therapeutics, Inc. Amended and Restated 2009 Stock Incentive Plan (the Plan). Pursuant to Rule 416(c) under the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of the Registrant's common stock that become issuable under the Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction that increases the number of the outstanding shares of the Registrant's common stock.
- (2) Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(c) of the Securities Act of 1933, as amended, using the last sale price reported on The NASDAQ Capital Market on August 21, 2014.

INFORMATION REQUIRED PURSUANT TO GENERAL INSTRUCTION E ON FORM S-8

This Registration Statement is filed by Sorrento Therapeutics, Inc. (the Company) for the purpose of registering additional securities of the same class and relating to the same employee benefit plan as securities for which the Company has an effective Registration Statement on Form S-8. The Company had previously registered 1,560,000 shares of the Company s common stock, par value \$0.0001 per share (the Common Stock) under the Sorrento Therapeutics, Inc. Amended and Restated 2009 Stock Incentive Plan (the Plan) on Form S-8 (Registration No. 333-195487) filed with the Securities and Exchange Commission (the SEC) on April 25, 2014 (the Original Registration Statement). The number of shares available for issuance under the Plan was increased by 2,200,000 shares on June 19, 2014.

Pursuant to General Instruction E to Form S-8, the contents of the Original Registration Statement are incorporated by reference into this Registration Statement.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The Company hereby incorporates by reference into this Registration Statement the following documents previously filed with the SEC:

Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on April 1, 2014;

Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2014 filed with the SEC on May 14, 2014;

Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2014 filed with the SEC on August 6, 2014;

Current Reports on Form 8-K (excluding any reports or portions thereof that are deemed to be furnished and not filed) filed with the SEC on January 9, 2014, February 3, 2014, March 11, 2014, April 1, 2014, April 4, 2014, May 13, 2014, May 15, 2014, May 30, 2014, June 23, 2014, June 25, 2014, July 1, 2014, July 21, 2014, July 31, 2014, August 8, 2014, August 18, 2014 and August 21, 2014;

The description of our common stock contained in our Form 8-A filed with the SEC on October 23, 2013; and

All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and prior to the filing of a post-effective amendment hereto, which indicates that all securities hereunder have been sold or which deregisters all securities remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Copies of these documents are not required to be filed with this Registration Statement, and nothing in this Registration Statement shall be deemed to incorporate information furnished but not filed with the SEC.

Item 8. Exhibits.

Exhibit Number	Description
5.1	Opinion of Sichenzia Ross Friedman Ference LLP
10.1	Amended and Restated 2009 Stock Incentive Plan
23.1	Consent of Mayer Hoffman McCann P.C.
23.2	Consent of Sichenzia Ross Friedman Ference LLP (included in Exhibit 5.1)
24.1	Power of Attorney (included on signature page)

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California, on the 22nd day of August 2014.

SORRENTO THERAPEUTICS INC.

By: /s/ Henry Ji
Henry Ji
Chief Executive Officer and President
(Principal Executive Officer)

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned constitutes and appoints Henry Ji and Richard Vincent, and each of them acting alone, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, the following persons in the capacities and on the dates indicated have signed this Registration Statement below.

Signature	Title	Date
/s/ Henry Ji Henry Ji	Director, Chief Executive Officer and President (Principal Executive Officer)	August 22, 2014
/s/ Richard G. Vincent Richard G. Vincent	Chief Financial Officer (Principal Financial and Accounting Officer)	August 22, 2014
/s/ William S. Marth William S. Marth	Director and Chairman	August 22, 2014
/s/ Jaisim Shah Jaisim Shah	Director	August 22, 2014

Edgar Filing: Sorrento Therapeutics, Inc. - Form S-8

/s/ Douglas Ebersole	Director	August 22, 2014
Douglas Ebersole		
/s/ Kim D. Janda	Director	August 22, 2014
Kim D. Janda		
/s/ Mark Durand	Director	August 22, 2014
Mark Durand		

EXHIBIT INDEX

Exhibit Number	Description
5.1	Opinion of Sichenzia Ross Friedman Ference LLP
10.1	Amended and Restated 2009 Stock Incentive Plan
23.1	Consent of Mayer Hoffman McCann P.C.
23.2	Consent of Sichenzia Ross Friedman Ference LLP (included in Exhibit 5.1)
24.1	Power of Attorney (included on signature page)